Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598899 | 0.97 | MEN1 (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104058 | 0.93 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL369080 | 0.91 | MAPT (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1341087 | 0.91 | MAPT (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL167529 | 0.90 | MEN1 (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL426250 | 0.89 | MEN1 (0.37) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4410135 | 0.89 | MEN1 (0.37) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6112028 | 0.89 | MEN1 (0.37) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4704955 | 0.88 | MAPT (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL15995586 | 0.88 | ACE2 (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11988667-B2 | Fluorescent compound and fluorescent labeled biological substance using the same | FUJIFILM CORPORATION (JP) | 2024-05-21 | — | — | US | disclosed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024101337-A1 | QUINAZOLINE DERIVATIVES | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024095964-A1 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | アステラス製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| US-20240101572-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-28 | — | — | US | disclosed |
| WO-2023243686-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-12-21 | — | — | WO | disclosed |
| CN-111132963-B | Compound, composition, cured product, and method for producing cured product | 株式会社艾迪科 | 2023-11-24 | — | — | CN | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5470975-A | Dihydropyrimidine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0481448-A1 | Dihydropyrimidine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1992-04-22 | — | — | EP | disclosed |
| CN-1057263-A | [3H, 7H] thiazole that respiratory tract is had anti-asthma and an anti-inflammatory effect is [3,4-α] pyridine also | BOEHRINGER MANNHEIM ITALIA (IT) | 1991-12-25 | — | — | CN | disclosed |
| EP-0396065-A1 | Novel amino acid derivatives possessing renin-inhibitory activities | Japan Tobacco Inc. (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4582644-A | Epi-ethynylation process | THE UPJOHN COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | MEN1 1930/4885MAPT 3374/4885KMT2A 1226/4885 |
| US-20240101572-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | PLD2, PLD1, PLD4 | MEN1 2622/4885MAPT 4171/4885KMT2A 2993/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MEN1 329/4885MAPT 3979/4885KMT2A 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.